{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:48:15Z","timestamp":1783676895631,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Health Science and Technology Project of\u00a0Zhejiang\u00a0Provincial\u00a0Health Commission","award":["2021KY765"],"award-info":[{"award-number":["2021KY765"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-026-01186-8","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:24:47Z","timestamp":1769487887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["JAK inhibitors for the treatment of juvenile localized scleroderma: a case report and literature review"],"prefix":"10.1186","volume":"24","author":[{"given":"Rongjun","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"1","key":"1186_CR1","first-page":"73","volume":"24","author":"LS Peterson","year":"1997","unstructured":"Peterson LS, Nelson AM, Su WP, Mason T, O\u2019Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in olmsted County 1960\u20131993. J Rhuematol. 1997;24(1):73\u201380.","journal-title":"J Rhuematol"},{"issue":"2","key":"1186_CR2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/acr.20070","volume":"62","author":"AL Herrick","year":"2010","unstructured":"Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res. 2010;62(2):213\u20138.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"1186_CR3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.rdc.2021.07.014","volume":"47","author":"N Vasquez-Canizares","year":"2021","unstructured":"Vasquez-Canizares N, Li SC. Juvenile localized scleroderma: updates and differences from Adult-Onset disease. Rheum Dis Clin North Am. 2021;47(4):737\u201355.","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"1186_CR4","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1093\/rheumatology\/keab238","volume":"60","author":"SC Li","year":"2021","unstructured":"Li SC, Higgins GC, Chen M, Torok KS, Rabinovich CE, Stewart K, Laxer RM, Pope E, Haines KA, Punaro M, et al. Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma. Rheumatology (Oxford). 2021;60(12):5724\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1186_CR5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/acr.23101","volume":"69","author":"K Ardalan","year":"2017","unstructured":"Ardalan K, Zigler CK, Torok KS. Predictors of longitudinal quality of life in juvenile localized scleroderma. Arthritis Care Res. 2017;69(7):1082\u20137.","journal-title":"Arthritis Care Res"},{"key":"1186_CR6","doi-asserted-by":"crossref","unstructured":"Li SC, Torok KS. Initial results from a pilot comparative effectiveness study of 3 methotrexate-based consensus treatment plans for juvenile localized scleroderma. 2020, 47(8):1242\u201352.","DOI":"10.3899\/jrheum.190311"},{"issue":"8","key":"1186_CR7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","volume":"78","author":"F Zulian","year":"2019","unstructured":"Zulian F, Culpo R, Sperotto F, Anton J, Avcin T, Baildam EM, Boros C, Chaitow J, Constantin T, Kasapcopur O, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019;78(8):1019\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1186_CR8","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","volume":"64","author":"SC Li","year":"2012","unstructured":"Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res. 2012;64(8):1175\u201385.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"1186_CR9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","volume":"31","author":"R Knobler","year":"2017","unstructured":"Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatology Venereology: JEADV. 2017;31(9):1401\u201324.","journal-title":"J Eur Acad Dermatology Venereology: JEADV"},{"issue":"7","key":"1186_CR10","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","volume":"63","author":"F Zulian","year":"2011","unstructured":"Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, Alessio M, La Torre F, Podda RA, Gerloni V, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998\u20132006.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1186_CR11","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, Horn A, Zerr P, Zwerina J, Gelse K, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum. 2012;64(9):3006\u201315.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1186_CR12","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jid.2019.12.019","volume":"140","author":"W Damsky","year":"2020","unstructured":"Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. Jak Inhibition prevents Bleomycin-Induced fibrosis in mice and is effective in patients with morphea. J Invest Dermatol. 2020;140(7):1446\u2013e14491444.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1186_CR13","doi-asserted-by":"crossref","first-page":"e15437","DOI":"10.1111\/dth.15437","volume":"35","author":"S McGaugh","year":"2022","unstructured":"McGaugh S, Kallis P, De Benedetto A, Thomas RM. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review. Dermatol Ther. 2022;35(6):e15437.","journal-title":"Dermatol Ther"},{"key":"1186_CR14","doi-asserted-by":"publisher","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of upadacitinib retreatment after withdrawal in moderate-to-severe atopic dermatitis: a retrospective study. Clin Exp Dermatol. 2025;50(4):770\u20138. https:\/\/doi.org\/10.1093\/ced\/llae410. PMID: 39378322.","DOI":"10.1093\/ced\/llae410"},{"key":"1186_CR15","doi-asserted-by":"crossref","first-page":"100756","DOI":"10.1016\/j.curtheres.2024.100756","volume":"101","author":"Y Liu","year":"2024","unstructured":"Liu Y, Song X, Xiang L, Tan W, Zou M, Guo H. Rapid remission with Upadacitinib in a child with refractory crohn\u2019s disease and ATM mutation: A case report. Curr Therapeutic Res Clin Experimental. 2024;101:100756.","journal-title":"Curr Therapeutic Res Clin Experimental"},{"key":"1186_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdcr.2024.06.033","volume":"51","author":"A Sohn","year":"2024","unstructured":"Sohn A, Bouch\u00e9 N, Lewitt GM, Song EJ. Successful treatment of refractory amyopathic dermatomyositis with Upadacitinib in prior JAK inhibitor failure. JAAD Case Rep. 2024;51:97\u20139.","journal-title":"JAAD Case Rep"},{"issue":"7","key":"1186_CR17","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","volume":"21","author":"S Friedberg","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T, Choi NK, Garcia NM, Picker EA, Cohen NA, Cohen RD, Dalal SR, Pekow J, et al. Upadacitinib is effective and safe in both ulcerative colitis and crohn\u2019s disease: prospective Real-World experience. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2023;21(7):1913\u201323. e1912.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"key":"1186_CR18","doi-asserted-by":"crossref","unstructured":"Napolitano M, D\u2019Amico F, Ragaini E. Evaluating upadacitinib in the treatment of moderate-to-severe active ulcerative colitis: Design, development, and potential position in therapy. 2022, 16:1897\u2013913.","DOI":"10.2147\/DDDT.S340459"},{"key":"1186_CR19","doi-asserted-by":"crossref","unstructured":"Ansari MS, Vahabi SM, Memari H, Hosseini F, Bahramian S, Etesami I. Use of the oral Janus kinase inhibitor Tofacitinib in the treatment of morphea: a retrospective study. J Am Acad Dermatol 2025.","DOI":"10.1016\/j.jaad.2025.05.1377"},{"key":"1186_CR20","doi-asserted-by":"crossref","unstructured":"Colussi L, Dagri A, Pastore S. Effect of the Janus kinase inhibitor Tofacitinib in the treatment of juvenile scleroderma: a single-center experience. 2024, 27(8):e15295.","DOI":"10.1111\/1756-185X.15295"},{"key":"1186_CR21","doi-asserted-by":"crossref","first-page":"adv4805","DOI":"10.2340\/actadv.v103.4805","volume":"103","author":"JC Tang","year":"2023","unstructured":"Tang JC, Zheng WY, Han GM, Liu SF, Yang B. Successful treatment of paediatric morphea with Tofacitinib. Acta dermato-venereologica. 2023;103:adv4805.","journal-title":"Acta dermato-venereologica"},{"key":"1186_CR22","first-page":"26","volume":"358","author":"M Osminina","year":"2025","unstructured":"Osminina M, Podchernyaeva N, Seraya V, Kurbanova S, Batureva O, Chebusheva S, Shpitonkova O, Polyanskaya A, Skakodub A, Ziskina N. EFFICACY AND TOLERABILITY OF JANUS KINASE INHIBITOR TOFACITINIB IN JUVENILE LINEAR SCLERODERMA. CASE SERIES OF 5 PATIENTS. Georgian Med News. 2025;358:26\u201330.","journal-title":"Georgian Med News"},{"key":"1186_CR23","doi-asserted-by":"crossref","unstructured":"Liu L, Zhan Y. Bullous lichen sclerosus-generalized morphea overlap syndrome improved by Tofacitinib. 2022, 35(12):e15942.","DOI":"10.1111\/dth.15942"},{"issue":"9","key":"1186_CR24","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1007\/s10067-020-05118-z","volume":"39","author":"M Scheinberg","year":"2020","unstructured":"Scheinberg M, Sabbagh C, Ferreira S, Michalany N. Full histological and clinical regression of morphea with Tofacitinib. Clin Rheumatol. 2020;39(9):2827\u20138.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1186_CR25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.23736\/S2784-8671.24.07925-8","volume":"159","author":"G Russo","year":"2024","unstructured":"Russo G, Dumont S, Laffitte E. Successful therapy of refractory cutaneous morphea with Tofacitinib. Italian J Dermatology Venereol. 2024;159(4):469\u201370.","journal-title":"Italian J Dermatology Venereol"},{"issue":"5","key":"1186_CR26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","volume":"4","author":"SR Kim","year":"2018","unstructured":"Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor Tofacitinib. JAAD Case Rep. 2018;4(5):443\u20135.","journal-title":"JAAD Case Rep"},{"key":"1186_CR27","doi-asserted-by":"crossref","unstructured":"Zou Q, Wei R. Successful treatment with baricitinib of linear morphea following the lines of blaschko mimicking lichen striatus. 2024, 51(1):115\u20139.","DOI":"10.1111\/1346-8138.16980"},{"key":"1186_CR28","doi-asserted-by":"crossref","unstructured":"Labrandero Hoyos C, Pe\u00f1uelas Leal R. JAK-STAT pathway is involved in cutaneous sclerosis processes: generalized morphea successfully treated with baricitinib. 2023, 50(12):e424\u20135.","DOI":"10.1111\/1346-8138.16933"},{"key":"1186_CR29","doi-asserted-by":"crossref","unstructured":"Soh HJ, Samuel C. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review. 2019, 39(5):933\u201341.","DOI":"10.1007\/s00296-019-04269-w"},{"key":"1186_CR30","doi-asserted-by":"crossref","unstructured":"Baghdassarian H, Blackstone SA, Clay OS. Variant STAT4 and response to ruxolitinib in an autoinflammatory syndrome. 2023, 388(24):2241\u201352.","DOI":"10.1056\/NEJMoa2202318"},{"key":"1186_CR31","doi-asserted-by":"crossref","unstructured":"Maione V, Rovaris S, Roman\u00f2 C, Bighetti S. Upadacinib for the treatment of refractory morphea. 2025, 66(4):238\u20139.","DOI":"10.1111\/ajd.14481"},{"issue":"3","key":"1186_CR32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/imt-2020-0270","volume":"13","author":"R Talotta","year":"2021","unstructured":"Talotta R. The rationale for targeting the JAK\/STAT pathway in scleroderma-associated interstitial lung disease. Immunotherapy. 2021;13(3):241\u201356.","journal-title":"Immunotherapy"},{"issue":"3","key":"1186_CR33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","volume":"101","author":"WW Aung","year":"2021","unstructured":"Aung WW, Wang C, Xibei J, Horii M, Mizumaki K, Kano M, Okamura A, Kobayashi T, Matsushita T. Immunomodulating role of the JAKs inhibitor Tofacitinib in a mouse model of bleomycin-induced scleroderma. J Dermatol Sci. 2021;101(3):174\u201384.","journal-title":"J Dermatol Sci"},{"issue":"24","key":"1186_CR34","first-page":"2120","volume":"69","author":"K Traynor","year":"2012","unstructured":"Traynor K. FDA approves Tofacitinib for rheumatoid arthritis. Am J health-system Pharmacy: AJHP : Official J Am Soc Health-System Pharmacists. 2012;69(24):2120.","journal-title":"Am J health-system Pharmacy: AJHP : Official J Am Soc Health-System Pharmacists"},{"issue":"5","key":"1186_CR35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/1744666X.2022.2060822","volume":"18","author":"S Narla","year":"2022","unstructured":"Narla S, Silverberg JI. The suitability of treating atopic dermatitis with Janus kinase inhibitors. Expert Rev Clin Immunol. 2022;18(5):439\u201359.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9993","key":"1186_CR36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet (London England). 2015;386(9993):552\u201361.","journal-title":"Lancet (London England)"},{"issue":"5","key":"1186_CR37","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, et al. Efficacy and safety of upadacitinib treatment in adolescents with Moderate-to-Severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials. JAMA Dermatology. 2023;159(5):526\u201335.","journal-title":"JAMA Dermatology"},{"issue":"9","key":"1186_CR38","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","volume":"21","author":"L Boneschansker","year":"2023","unstructured":"Boneschansker L, Ananthakrishnan AN. Comparative effectiveness of Upadacitinib and Tofacitinib in inducing remission in ulcerative colitis: Real-World data. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2023;21(9):2427\u2013e24292421.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"2","key":"1186_CR39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"25","key":"1186_CR40","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386.","journal-title":"N Engl J Med"},{"issue":"3","key":"1186_CR41","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, et al. Baricitinib, Methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior Disease-Modifying antirheumatic drug treatment. Arthritis Rheumatol (Hoboken NJ). 2017;69(3):506\u201317.","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"issue":"10188","key":"1186_CR42","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet (London England). 2019;393(10188):2303\u201311.","journal-title":"Lancet (London England)"},{"key":"1186_CR43","doi-asserted-by":"crossref","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, Rischmueller M, Blanco R. Efficacy and safety of Upadacitinib monotherapy in Methotrexate-Naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, active Comparator-Controlled trial. 2020, 72(10):1607\u201320.","DOI":"10.1002\/art.41384"},{"key":"1186_CR44","doi-asserted-by":"crossref","unstructured":"Fleischmann RM, Genovese MC. Safety and effectiveness of Upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. 2019, 78(11):1454\u201362.","DOI":"10.1136\/annrheumdis-2019-215764"},{"issue":"10093","key":"1186_CR45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, et al. Efficacy and safety of Tofacitinib monotherapy, Tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet (London England). 2017;390(10093):457\u201368.","journal-title":"Lancet (London England)"},{"key":"1186_CR46","doi-asserted-by":"crossref","unstructured":"Brunner HI, Akikusa JD, Al-Abadi E. Safety and efficacy of Tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. 2024, 83(11):1561\u201371.","DOI":"10.1136\/ard-2023-225094"},{"issue":"10401","key":"1186_CR47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","volume":"402","author":"AV Ramanan","year":"2023","unstructured":"Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutov\u00e1 \u0160, Ant\u00f3n J, Wang Z, Meszaros G, Ara\u00fajo J, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet (London England). 2023;402(10401):555\u201370.","journal-title":"Lancet (London England)"},{"issue":"11","key":"1186_CR48","first-page":"1788","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, Double-Blind. Randomized Controlled Trial. 2019;71(11):1788\u2013800.","journal-title":"Randomized Controlled Trial"},{"issue":"13","key":"1186_CR49","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, Jeka S, Pacheco-Tena C, Wang X, Chen L, et al. Trial of Upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227\u201339.","journal-title":"N Engl J Med"},{"key":"1186_CR50","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Baraliakos X. Efficacy and safety of Upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. 2022, 81(11):1515\u201323.","DOI":"10.1136\/ard-2022-222608"},{"issue":"3","key":"1186_CR51","doi-asserted-by":"crossref","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","volume":"6","author":"MC Baker","year":"2023","unstructured":"Baker MC, Liu Y, Lu R, Lin J, Melehani J, Robinson WH. Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-Modifying antirheumatic drugs. JAMA Netw Open. 2023;6(3):e233640.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1186_CR52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-023-03170-z","volume":"25","author":"J Zhang","year":"2023","unstructured":"Zhang J, Sun L, Shi X, Li S, Liu C, Li X, Lu M, Deng J, Tan X, Guan W, et al. Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China. Arthritis Res Therapy. 2023;25(1):204.","journal-title":"Arthritis Res Therapy"},{"issue":"9","key":"1186_CR53","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/09273948.2024.2323671","volume":"32","author":"P Dutta Majumder","year":"2024","unstructured":"Dutta Majumder P, Abraham S, Sudharshan S, Janarthanan M, Ramanan AV. Tofacitinib for refractory uveitis and scleritis in children: A case series. Ocul Immunol Inflamm. 2024;32(9):2092\u20135.","journal-title":"Ocul Immunol Inflamm"},{"key":"1186_CR54","doi-asserted-by":"crossref","first-page":"1439338","DOI":"10.3389\/fmed.2024.1439338","volume":"11","author":"A Vitale","year":"2024","unstructured":"Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hern\u00e1ndez-Rodr\u00edguez J, Pelegr\u00edn L, Mej\u00eda-Salgado G, Zarate-Pinz\u00f3n L, Gentileschi S, Sota J, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries. Front Med. 2024;11:1439338.","journal-title":"Front Med"},{"issue":"3","key":"1186_CR55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.31138\/mjr.20230828.ti","volume":"34","author":"S Dey","year":"2023","unstructured":"Dey S, Sarkar R, Pradhan A, Padhan P, Maikap D. Tofacitinib in refractory scleritis: A case series. Mediterranean J Rheumatol. 2023;34(3):367\u201371.","journal-title":"Mediterranean J Rheumatol"},{"issue":"1","key":"1186_CR56","first-page":"4","volume":"27","author":"MMK Shalabi","year":"2022","unstructured":"Shalabi MMK, Garcia B, Coleman K, Siller A Jr., Miller AC, Tyring SK. Janus kinase and tyrosine kinase inhibitors in dermatology: A review of their Utilization, safety profile and future applications. Skin Ther Lett. 2022;27(1):4\u20139.","journal-title":"Skin Ther Lett"},{"issue":"4","key":"1186_CR57","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1186_CR58","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","volume":"86","author":"S Chapman","year":"2022","unstructured":"Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part II. A comprehensive review. J Am Acad Dermatol. 2022;86(2):414\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1186_CR59","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","volume":"66","author":"S Cohen","year":"2014","unstructured":"Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of Tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol (Hoboken NJ). 2014;66(11):2924\u201337.","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"issue":"7","key":"1186_CR60","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, et al. Long-term safety of Tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"10139","key":"1186_CR61","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL. Safety and efficacy of Upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet (London England). 2018;391(10139):2513\u201324.","journal-title":"Lancet (London England)"},{"key":"1186_CR62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Therapy. 2016;18:34.","journal-title":"Arthritis Res Therapy"},{"issue":"5","key":"1186_CR63","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, Soma K, Wang L, Riese R. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1186_CR64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1186_CR65","doi-asserted-by":"crossref","unstructured":"Angelini J, Talotta R. JAK-Inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. 2020, 10(7).","DOI":"10.3390\/biom10071002"},{"issue":"10","key":"1186_CR66","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, Kawabata T, Riese R. Herpes Zoster and Tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol (Hoboken NJ). 2014;66(10):2675\u201384.","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"issue":"4","key":"1186_CR67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479\u201388.","journal-title":"Haematologica"},{"issue":"1","key":"1186_CR68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/14397595.2019.1583711","volume":"30","author":"M Harigai","year":"2020","unstructured":"Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, et al. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phases 2 and 3 trials. Mod Rheumatol. 2020;30(1):36\u201343.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1186_CR69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1186_CR70","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","volume":"15","author":"RA Mesa","year":"2015","unstructured":"Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015;15(4):214\u2013e221211.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1186_CR71","doi-asserted-by":"crossref","unstructured":"Huang L, Zhao D, Lin H, Zheng H, Li X, Chen L, Tang P. Efficacy and safety of Upadacitinib in the treatment of moderate-to-severe atopic dermatitis in adolescents: A systematic review and meta-analysis of randomized controlled trials. 2024, 103(38):e39826.","DOI":"10.1097\/MD.0000000000039826"},{"key":"1186_CR72","doi-asserted-by":"crossref","unstructured":"Burmester GR, Cohen SB. Safety profile of Upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. 2023, 9(1).","DOI":"10.1136\/rmdopen-2022-002735"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01186-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:29:19Z","timestamp":1771421359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01186-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Children\u2019s Hospital, Zhejiang University School of Medicine(2024-IRB-0146-P-01). The child and his parents signed the informed consent.for participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent for participate"}},{"value":"Written consent was obtained from the patient and the parents for publishing this.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}